Table of Contents
ISRN Dermatology
Volume 2012, Article ID 680163, 5 pages
Review Article

New Concepts in Median Nail Dystrophy, Onychomycosis, and Hand, Foot, and Mouth Disease Nail Pathology

1Faculty of Medicine, University of Alberta, Edmonton, AB, Canada T6G 2R7
2Department of Pediatrics, University of Calgary, Calgary, AB, Canada T2N 4N1
3Department of Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1

Received 9 November 2011; Accepted 4 December 2011

Academic Editor: M. Alaibac

Copyright © 2012 Nathan Y. Hoy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nails are underutilized as diagnostic tools, despite being involved in many dermatologic conditions. This paper explores new concepts in the treatment of median nail dystrophy (MND), onychomycosis, and the nail pathology of hand, foot, and mouth disease (HFMD). A Pubmed database literature search was conducted for MND treatment, onychomycosis treatment, and HFMD nail pathology. Only papers published after January 2008 were reviewed. The results showed that 0.1% tacrolimus ointment can be an effective treatment for MND. Early studies on laser therapy indicate that it is a safe and efficacious treatment option for onychomycosis, compared to conventional oral antifungal agents. Vicks VapoRub (The Proctor & Gamble Company, Cincinnati, OH) is effective against onychomycosis and is a reasonable option in patients who choose to forgo conventional treatments. Lastly, there is evidence to support a correlation between HFMD and onychomadesis.